To improve outcome prediction, we assessed the prognostic impact of free light chain and IgM abnormalities on DLBCL outcome in a post hoc analysis of the PETAL trial and correlated the findings with FDG-PET/CT data and molecular markers detected in tumor biopsies and circulating tumor DNA (ctDNA). Here, CD40LG is linked to diffuse large B-cell lymphoma.